Trastuzumab-induced cardiotoxicity: Heart failure at the crossroads

Mayo Clinic Proceedings

Volumn 83, Issue 2, 2008, Pages 197-203

  Sengupta, Partho P ^a   Northfelt, Donald W ^a   Gentile, Federico ^a   Zamorano, Jose L ^b   Khandheria, Bijoy K ^a  

^a MAYO CLINIC   (United States)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBOPLATIN; CARDIAC GLYCOSIDE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; INOTROPIC AGENT; LAPATINIB; NAVELBINE; PACLITAXEL; TRASTUZUMAB;

BREAST CANCER; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DRUG WITHDRAWAL; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; METASTASIS; PREVALENCE; RADIOISOTOPE VENTRICULOGRAPHY; REVIEW; RISK FACTOR; SIDE EFFECT; SURVIVAL RATE; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

EID: 39749097363     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/83.2.197     Document Type: Review

References (43)

1. R Ng N Better MD Green Anticancer agents and cardiotoxicity Semin Oncol 33 1 2006 2 14
2. ML Telli SA Hunt RW Carlson AE Guardino Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility J Clin Oncol 25 23 2007 3525 3533
3. AM Feldman BH Lorell SE Reis Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity Circulation 102 3 2000 272 274
4. DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 4785 1987 177 182
5. MD Pegram T Pienkowski DW Northfelt Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer J Natl Cancer Inst 96 10 2004 759 769
6. J Baselga D Tripathy J Mendelsohn Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer J Clin Oncol 14 3 1996 737 744
7. MA Cobleigh CL Vogel D Tripathy Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 9 1999 2639 2648
8. DJ Slamon B Leyland-Jones S Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 11 2001 783 792
9. M Marty F Cognetti D Maraninchi Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 19 2005 Jul 1 4265 4274 Epub 2005 May 23.
10. J Baselga EA Perez T Pienkowski R Bell Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer Oncologist 11 suppl 1 2006 4 12
11. MJ Piccart-Gebhart M Procter B Leyland-Jones Herceptin Adjuvant (HERA) Trial Study Team Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 16 2005 1659 1672
12. H Joensuu PL Kellokumpu-Lehtinen P Bono FinHer Study Investigatiors. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354 8 2006 809 820
13. E Tan-Chiu G Yothers E Romond Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31 J Clin Oncol 23 31 2005 7811 7819
14. A Lin HS Rugo The role of trastuzumab in early stage breast cancer: current data and treatment recommendations Curr Treat Options Oncol 8 1 2007 47 60
15. KR Chien Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity Semin Oncol 27 6 suppl 11 2000 9 14
16. A Seidman C Hudis MK Pierri Cardiac dysfunction in the trastuzumab clinical trials experience J Clin Oncol 20 5 2002 1215 1221
17. GS Panjrath D Jain Trastuzumab-induced cardiac dysfunction [editorial] Nucl Med Commun 28 2 2007 69 73
18. Bria E, Cuppone F, Fornier M. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials [published online ahead of print July 19, 2007]. Breast Cancer Res Treat, doi:10.1007/s10549-007-9663-z.
19. MS Ewer MT Vooletich JB Durand Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment J Clin Oncol 23 31 2005 7820 7826
20. EA Perez R Rodeheffer Clinical cardiac tolerability of trastuzumab J Clin Oncol 22 2 2004 322 329
21. MC Pinder Z Duan JS Goodwin GN Hortobagyi SH Giordano Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer J Clin Oncol 25 25 2007 Sep 1 3808 3815 Epub 2007 Jul 30.
22. AN Garratt C Ozcelik C Birchmeier ErbB2 pathways in heart and neural diseases Trends Cardiovasc Med 13 2 2003 80 86
23. KR Chien Herceptin and the heart—a molecular modifier of cardiac failure N Engl J Med 354 8 2006 789 790
24. SA Crone YY Zhao L Fan ErbB2 is essential in the prevention of dilated cardiomyopathy Nat Med 8 5 2002 459 465
25. C Ozcelik B Erdmann B Pilz Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy Proc Natl Acad Sci U S A 99 13 2002 Jun 25 8880 8885 Epub 2002 Jun 18.
26. NJ Freedman GS Ginsburg Novel—and “neu”—therapeutic possibilities for heart failure [editorial] J Am Coll Cardiol 48 7 2006 Oct 3 1448 1450 Epub 2006 Sep 14.
27. K Lemmens K Doggen GW De Keulenaer Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure Circulation 116 8 2007 954 960
28. MA de Korte EG de Vries MN Lub-de Hooge Indiumtrastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity Eur J Cancer 43 14 2007 Sep 2046 2051 Epub 2007 Aug 24.
29. B Moy P Kirkpatrick S Kar P. Goss Lapatinib Nat Rev Drug Discov 6 6 2007 431 432
30. T Force DS Krause RA Van Etten Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition Nat Rev Cancer 7 5 2007 332 344
31. V Guarneri DJ Lenihan V Valero Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience J Clin Oncol 24 25 2006 Sep 1 4107 4115 Epub 2006 Aug 14.
32. SA Hunt Writing Committee Members ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) J Am Coll Cardiol 46 6 2005 e1 e82
33. PM Klein N Dybdal Trastuzumab and cardiac dysfunction: update on preclinical studies Semin Oncol 30 5 suppl 16 2003 49 53
34. EH Romond EA Perez J Bryant Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 16 2005 1673 1684
35. KF Fox The evaluation of left ventricular function for patients being considered for, or receiving Trastuzumab (Herceptin) therapy [letter] Br J Cancer 95 10 2006 Nov 20 1454 Epub 2006 Oct 24.
36. Heart Failure Society of America Executive summary. HFSA 2006 Comprehensive Heart Failure Practice Guideline J Card Fail 12 1 2006 10 38
37. GW De Keulenaer DL Brutsaert Diastolic heart failure: a separate disease or selection bias? Prog Cardiovasc Dis 49 4 2007 275 283
38. JE Sanderson AG Fraser Systolic dysfunction in heart failure with a normal ejection fraction: echo-Doppler measurements Prog Cardiovasc Dis 49 3 2006 196 206
39. F Weidemann JM Strotmann Detection of subclinical LV dysfunction by tissue Doppler imaging [editorial] Eur Heart J 27 15 2006 Aug 1771 1772 Epub 2006 Jul 10.
40. L Kapusta JM Thijssen J Groot-Loonen T Antonius J Mulder O Daniels Tissue Doppler imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines Ultrasound Med Biol 26 7 2000 1099 1108
41. JA Sparano DL Brown AC Wolff Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers Drug Saf 25 5 2002 301 311
42. PJ Perik MN Lub-De Hooge JA Gietema Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer J Clin Oncol 24 15 2006 2276 2282
43. LW Jones MJ Haykowsky JJ Swartz PS Douglas JR Mackey Early breast cancer therapy and cardiovascular injury J Am Coll Cardiol 50 15 2007 Oct 9 1435 1441 Epub 2007 Sep 24.